Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618613 · ClinicalTrials.gov registry record · Phase 1
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
A Phase 1 study, sponsored by Context Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05618613 is a Phase 1 study that was terminated before completion, run by Context Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT05618613, a Phase 1 study, was terminated before completion, sponsored by Context Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
Interventions
- DRUG Elacestrant
- DRUG Onapristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-12-02 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05618613
The ClinicalTrials.gov registry entry for NCT05618613 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Context Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Elacestrant is the first listed.
NCT05618613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05618613 about?
NCT05618613 is a clinical study titled "Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer". This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
What is the current status of trial NCT05618613?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-12-02. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05618613?
The interventions under investigation include: Elacestrant (DRUG), Onapristone (DRUG).
Who is sponsoring clinical trial NCT05618613?
This trial is sponsored by Context Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.